Application of moisturizer to neonates prevents development of atopic dermatitis

Kenta Horimukai, Kumiko Morita, Masami Narita, Mai Kondo, Hiroshi Kitazawa, Makoto Nozaki, Yukiko Shigematsu, Kazue Yoshida, Hironori Niizeki, Ken Ichiro Motomura, Haruhiko Sago, Tetsuya Takimoto, Eisuke Inoue, Norio Kamemura, Hiroshi Kido, Junzo Hisatsune, Motoyuki Sugai, Hiroyuki Murota, Ichiro Katayama, Takashi Sasaki & 6 others Masayuki Amagai, Hideaki Morita, Akio Matsuda, Kenji Matsumoto, Hirohisa Saito, Yukihiro Ohya

Research output: Contribution to journalArticle

248 Citations (Scopus)

Abstract

Results Approximately 32% fewer neonates who received the moisturizer had AD/eczema by week 32 than control subjects (P =.012, log-rank test). We did not show a statistically significant effect of emollient on allergic sensitization based on the level of IgE antibody against egg white at 0.34 kUA/L CAP-FEIA equivalents. However, the sensitization rate was significantly higher in infants who had AD/eczema than in those who did not (odds ratio, 2.86; 95% CI, 1.22-6.73). Conclusion Daily application of moisturizer during the first 32 weeks of life reduces the risk of AD/eczema in infants. Allergic sensitization during this time period is associated with the presence of eczematous skin but not with moisturizer use.

Background Recent studies have suggested that epidermal barrier dysfunction contributes to the development of atopic dermatitis (AD) and other allergic diseases. Objective We performed a prospective, randomized controlled trial to investigate whether protecting the skin barrier with a moisturizer during the neonatal period prevents development of AD and allergic sensitization.

Methods An emulsion-type moisturizer was applied daily during the first 32 weeks of life to 59 of 118 neonates at high risk for AD (based on having a parent or sibling with AD) who were enrolled in this study. The onset of AD (eczematous symptoms lasting >4 weeks) and eczema (lasting >2 weeks) was assessed by a dermatology specialist on the basis of the modified Hanifin and Rajka criteria. The primary outcome was the cumulative incidence of AD plus eczema (AD/eczema) at week 32 of life. A secondary outcome, allergic sensitization, was evaluated based on serum levels of allergen-specific IgE determined by using a high-sensitivity allergen microarray of diamond-like carbon-coated chips.

Original languageEnglish
Pages (from-to)824-830.e6
JournalJournal of Allergy and Clinical Immunology
Volume134
Issue number4
DOIs
Publication statusPublished - 2014 Oct 1

Fingerprint

Atopic Dermatitis
Newborn Infant
Eczema
Allergens
Immunoglobulin E
Emollients
Egg White
Skin
Diamond
Dermatology
Emulsions
Siblings
Carbon
Randomized Controlled Trials
Odds Ratio

Keywords

  • allergic sensitization
  • Atopic dermatitis
  • atopy
  • food allergy
  • IgE
  • randomized controlled trial

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)

Cite this

Application of moisturizer to neonates prevents development of atopic dermatitis. / Horimukai, Kenta; Morita, Kumiko; Narita, Masami; Kondo, Mai; Kitazawa, Hiroshi; Nozaki, Makoto; Shigematsu, Yukiko; Yoshida, Kazue; Niizeki, Hironori; Motomura, Ken Ichiro; Sago, Haruhiko; Takimoto, Tetsuya; Inoue, Eisuke; Kamemura, Norio; Kido, Hiroshi; Hisatsune, Junzo; Sugai, Motoyuki; Murota, Hiroyuki; Katayama, Ichiro; Sasaki, Takashi; Amagai, Masayuki; Morita, Hideaki; Matsuda, Akio; Matsumoto, Kenji; Saito, Hirohisa; Ohya, Yukihiro.

In: Journal of Allergy and Clinical Immunology, Vol. 134, No. 4, 01.10.2014, p. 824-830.e6.

Research output: Contribution to journalArticle

Horimukai, K, Morita, K, Narita, M, Kondo, M, Kitazawa, H, Nozaki, M, Shigematsu, Y, Yoshida, K, Niizeki, H, Motomura, KI, Sago, H, Takimoto, T, Inoue, E, Kamemura, N, Kido, H, Hisatsune, J, Sugai, M, Murota, H, Katayama, I, Sasaki, T, Amagai, M, Morita, H, Matsuda, A, Matsumoto, K, Saito, H & Ohya, Y 2014, 'Application of moisturizer to neonates prevents development of atopic dermatitis', Journal of Allergy and Clinical Immunology, vol. 134, no. 4, pp. 824-830.e6. https://doi.org/10.1016/j.jaci.2014.07.060
Horimukai, Kenta ; Morita, Kumiko ; Narita, Masami ; Kondo, Mai ; Kitazawa, Hiroshi ; Nozaki, Makoto ; Shigematsu, Yukiko ; Yoshida, Kazue ; Niizeki, Hironori ; Motomura, Ken Ichiro ; Sago, Haruhiko ; Takimoto, Tetsuya ; Inoue, Eisuke ; Kamemura, Norio ; Kido, Hiroshi ; Hisatsune, Junzo ; Sugai, Motoyuki ; Murota, Hiroyuki ; Katayama, Ichiro ; Sasaki, Takashi ; Amagai, Masayuki ; Morita, Hideaki ; Matsuda, Akio ; Matsumoto, Kenji ; Saito, Hirohisa ; Ohya, Yukihiro. / Application of moisturizer to neonates prevents development of atopic dermatitis. In: Journal of Allergy and Clinical Immunology. 2014 ; Vol. 134, No. 4. pp. 824-830.e6.
@article{60f6dc80165a47c1afb3c0199ef4be86,
title = "Application of moisturizer to neonates prevents development of atopic dermatitis",
abstract = "Results Approximately 32{\%} fewer neonates who received the moisturizer had AD/eczema by week 32 than control subjects (P =.012, log-rank test). We did not show a statistically significant effect of emollient on allergic sensitization based on the level of IgE antibody against egg white at 0.34 kUA/L CAP-FEIA equivalents. However, the sensitization rate was significantly higher in infants who had AD/eczema than in those who did not (odds ratio, 2.86; 95{\%} CI, 1.22-6.73). Conclusion Daily application of moisturizer during the first 32 weeks of life reduces the risk of AD/eczema in infants. Allergic sensitization during this time period is associated with the presence of eczematous skin but not with moisturizer use.Background Recent studies have suggested that epidermal barrier dysfunction contributes to the development of atopic dermatitis (AD) and other allergic diseases. Objective We performed a prospective, randomized controlled trial to investigate whether protecting the skin barrier with a moisturizer during the neonatal period prevents development of AD and allergic sensitization.Methods An emulsion-type moisturizer was applied daily during the first 32 weeks of life to 59 of 118 neonates at high risk for AD (based on having a parent or sibling with AD) who were enrolled in this study. The onset of AD (eczematous symptoms lasting >4 weeks) and eczema (lasting >2 weeks) was assessed by a dermatology specialist on the basis of the modified Hanifin and Rajka criteria. The primary outcome was the cumulative incidence of AD plus eczema (AD/eczema) at week 32 of life. A secondary outcome, allergic sensitization, was evaluated based on serum levels of allergen-specific IgE determined by using a high-sensitivity allergen microarray of diamond-like carbon-coated chips.",
keywords = "allergic sensitization, Atopic dermatitis, atopy, food allergy, IgE, randomized controlled trial",
author = "Kenta Horimukai and Kumiko Morita and Masami Narita and Mai Kondo and Hiroshi Kitazawa and Makoto Nozaki and Yukiko Shigematsu and Kazue Yoshida and Hironori Niizeki and Motomura, {Ken Ichiro} and Haruhiko Sago and Tetsuya Takimoto and Eisuke Inoue and Norio Kamemura and Hiroshi Kido and Junzo Hisatsune and Motoyuki Sugai and Hiroyuki Murota and Ichiro Katayama and Takashi Sasaki and Masayuki Amagai and Hideaki Morita and Akio Matsuda and Kenji Matsumoto and Hirohisa Saito and Yukihiro Ohya",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.jaci.2014.07.060",
language = "English",
volume = "134",
pages = "824--830.e6",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Application of moisturizer to neonates prevents development of atopic dermatitis

AU - Horimukai, Kenta

AU - Morita, Kumiko

AU - Narita, Masami

AU - Kondo, Mai

AU - Kitazawa, Hiroshi

AU - Nozaki, Makoto

AU - Shigematsu, Yukiko

AU - Yoshida, Kazue

AU - Niizeki, Hironori

AU - Motomura, Ken Ichiro

AU - Sago, Haruhiko

AU - Takimoto, Tetsuya

AU - Inoue, Eisuke

AU - Kamemura, Norio

AU - Kido, Hiroshi

AU - Hisatsune, Junzo

AU - Sugai, Motoyuki

AU - Murota, Hiroyuki

AU - Katayama, Ichiro

AU - Sasaki, Takashi

AU - Amagai, Masayuki

AU - Morita, Hideaki

AU - Matsuda, Akio

AU - Matsumoto, Kenji

AU - Saito, Hirohisa

AU - Ohya, Yukihiro

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Results Approximately 32% fewer neonates who received the moisturizer had AD/eczema by week 32 than control subjects (P =.012, log-rank test). We did not show a statistically significant effect of emollient on allergic sensitization based on the level of IgE antibody against egg white at 0.34 kUA/L CAP-FEIA equivalents. However, the sensitization rate was significantly higher in infants who had AD/eczema than in those who did not (odds ratio, 2.86; 95% CI, 1.22-6.73). Conclusion Daily application of moisturizer during the first 32 weeks of life reduces the risk of AD/eczema in infants. Allergic sensitization during this time period is associated with the presence of eczematous skin but not with moisturizer use.Background Recent studies have suggested that epidermal barrier dysfunction contributes to the development of atopic dermatitis (AD) and other allergic diseases. Objective We performed a prospective, randomized controlled trial to investigate whether protecting the skin barrier with a moisturizer during the neonatal period prevents development of AD and allergic sensitization.Methods An emulsion-type moisturizer was applied daily during the first 32 weeks of life to 59 of 118 neonates at high risk for AD (based on having a parent or sibling with AD) who were enrolled in this study. The onset of AD (eczematous symptoms lasting >4 weeks) and eczema (lasting >2 weeks) was assessed by a dermatology specialist on the basis of the modified Hanifin and Rajka criteria. The primary outcome was the cumulative incidence of AD plus eczema (AD/eczema) at week 32 of life. A secondary outcome, allergic sensitization, was evaluated based on serum levels of allergen-specific IgE determined by using a high-sensitivity allergen microarray of diamond-like carbon-coated chips.

AB - Results Approximately 32% fewer neonates who received the moisturizer had AD/eczema by week 32 than control subjects (P =.012, log-rank test). We did not show a statistically significant effect of emollient on allergic sensitization based on the level of IgE antibody against egg white at 0.34 kUA/L CAP-FEIA equivalents. However, the sensitization rate was significantly higher in infants who had AD/eczema than in those who did not (odds ratio, 2.86; 95% CI, 1.22-6.73). Conclusion Daily application of moisturizer during the first 32 weeks of life reduces the risk of AD/eczema in infants. Allergic sensitization during this time period is associated with the presence of eczematous skin but not with moisturizer use.Background Recent studies have suggested that epidermal barrier dysfunction contributes to the development of atopic dermatitis (AD) and other allergic diseases. Objective We performed a prospective, randomized controlled trial to investigate whether protecting the skin barrier with a moisturizer during the neonatal period prevents development of AD and allergic sensitization.Methods An emulsion-type moisturizer was applied daily during the first 32 weeks of life to 59 of 118 neonates at high risk for AD (based on having a parent or sibling with AD) who were enrolled in this study. The onset of AD (eczematous symptoms lasting >4 weeks) and eczema (lasting >2 weeks) was assessed by a dermatology specialist on the basis of the modified Hanifin and Rajka criteria. The primary outcome was the cumulative incidence of AD plus eczema (AD/eczema) at week 32 of life. A secondary outcome, allergic sensitization, was evaluated based on serum levels of allergen-specific IgE determined by using a high-sensitivity allergen microarray of diamond-like carbon-coated chips.

KW - allergic sensitization

KW - Atopic dermatitis

KW - atopy

KW - food allergy

KW - IgE

KW - randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=84908111193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908111193&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2014.07.060

DO - 10.1016/j.jaci.2014.07.060

M3 - Article

VL - 134

SP - 824-830.e6

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -